title: Effects of indomethacin and polyunsaturated fatty acid diet on exercise-induced hypoxaemia in master athletes.
abstract: We have previously reported a reduction in exercise-induced hypoxaemia following polyunsaturated fatty acid supplementation (PUFA). Although this might have been explained by increases in membrane fluidity, a clear explanation could not be provided due to potentially confounding influences of series-2 prosta- glandin mediated effects resulting from PUFA. In this investigation, ten master athletes [mean age 48.1 (SEM 6) years, maximal oxygen uptake (VO2max) 3.39 (SEM 0.21) l x min(-1)] completed a maximal cycling test (Ctrl) which was repeated after the administration of 150 mg of indomethacin to inhibit prostaglandin synthesis, both before and after 6 weeks of 3.66-g PUFA x day(-1). Cardiorespiratory parameters were obtained simultaneously with brachial arterial blood sampling for partial pressure of oxygen in arterial blood (PaO2), partial pressure of carbon dioxide in arterial blood (PaCO2), pH, oxygen saturation in arterial blood and lactate concentration determinations. A significant decrease in PaO2 (mmHg) from rest [93 (SEM 1.5)] was observed for exercise intensities of more than 40% VO2max in Ctrl reaching 75.9 (SEM 2.1) at VO2max. PUFA resulted in a 5.0 (SEM 0.68) mmHg upward shift (P < 0.05) in the PaO2-oxygen uptake relationship, reducing the difference in partial pressure of oxygen between alveolar air and arterial blood (P(A-a)O2) at VO2max [Ctrl 36 (SEM 1.6) vs PUFA 33 (SEM 2.2) mmHg] while PaCO2, remained unchanged. Indomethacin had no effect on either PaO2, ideal partial pressure of oxygen in alveolar gas or P(A-a)O2 in either Ctrl or after PUFA. In contrast, the fall in pH was significantly reduced after indomethacin while VCO2, PaCO2 and lactacidaemia remained unchanged. These observations confirm an effect of PUFA on exercise PaO2 behaviour which does not appear to be mediated by the influence of a series-2 prostaglandin.
authors.affiliation: UCP. X, Laboratoire de physiopathologie de l'exercice, Grenoble, France.
authors.forename: B
authors.initials: B
authors.lastname: Aguilaniu
authors.forename: P
authors.initials: P
authors.lastname: Flore
authors.forename: E
authors.initials: E
authors.lastname: Page
authors.forename: J
authors.initials: J
authors.lastname: Maitre
authors.forename: J R
authors.initials: JR
authors.lastname: Lacour
authors.forename: H
authors.initials: H
authors.lastname: Perrault
mesh_terms: D000328:Adult; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D004042:Dietary Fats, Unsaturated / Q000008:administration & dosage*; D015444:Exercise / Q000502:physiology*; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D000860:Hypoxia / Q000209:etiology / Q000517:prevention & control*; D007213:Indomethacin / Q000494:pharmacology*; D019344:Lactic Acid / Q000097:blood; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D010101:Oxygen Consumption; D011453:Prostaglandins / Q000502:physiology; D011659:Pulmonary Gas Exchange; D012129:Respiratory Function Tests
chemical_list: D016861:Cyclooxygenase Inhibitors; D004042:Dietary Fats, Unsaturated; D005231:Fatty Acids, Unsaturated; D008055:Lipids; D011453:Prostaglandins; D019344:Lactic Acid; D010100:Oxygen; D007213:Indomethacin